These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 26345559)
1. [Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan]. Takamatsu Y; Muta T Rinsho Ketsueki; 2015 Aug; 56(8):1005-10. PubMed ID: 26345559 [TBL] [Abstract][Full Text] [Related]
2. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. González-Calle V; Dávila J; Escalante F; de Coca AG; Aguilera C; López R; Bárez A; Alonso JM; Hernández R; Hernández JM; de la Fuente P; Puig N; Ocio EM; Gutiérrez NC; García-Sanz R; Mateos MV Leukemia; 2016 Oct; 30(10):2026-2031. PubMed ID: 27133826 [TBL] [Abstract][Full Text] [Related]
3. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G; Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730 [TBL] [Abstract][Full Text] [Related]
4. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429 [TBL] [Abstract][Full Text] [Related]
5. Smoldering multiple myeloma. Gao M; Yang G; Kong Y; Wu X; Shi J Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300 [TBL] [Abstract][Full Text] [Related]
6. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management. Hillengass J; Moehler T; Hundemer M Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683 [TBL] [Abstract][Full Text] [Related]
10. Smoldering multiple myeloma: natural history and recognition of an evolving type. Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966 [TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755 [TBL] [Abstract][Full Text] [Related]
12. Smoldering multiple myeloma: when to observe and when to treat? Mateos MV; San Miguel JF Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213 [TBL] [Abstract][Full Text] [Related]